{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "A rotational thromboelastometry (ROTEM \u00ae ) guided transfusion strategy for obstetrics was implemented at our institution in September 2022."
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "944 women who experienced postpartum haemorrhage \u2265\u20091500\u2009ml over a 5\u2010year period"
      },
      "Intervention": {
        "score": 2,
        "evidence": "comparing 1\u2009year of data after the formal introduction of the ROTEM \u00ae \u2010guided transfusion strategy (post\u2010ROTEM \u00ae ) with the previous 4\u2009years, when a conventional transfusion strategy was in place based on standard laboratory tests (pre\u2010ROTEM \u00ae )."
      },
      "Objective": {
        "score": 1,
        "evidence": "The aim of the strategy was to facilitate timely, targeted administration of coagulation products based on viscoelastic haemostatic testing, thereby reducing unnecessary transfusions."
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "97/238 (40%) in the post\u2010ROTEM \u00ae group vs. 312/706 (44%) in the pre\u2010ROTEM group"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Following implementation, the annual use of fibrinogen concentrate, Octaplas \u00ae (Octapharma Pharmazeutika GmbH, Vienna, Austria) and platelets to treat PPH \u2265\u20091500\u2009ml decreased by 46%, 72% and 79%, respectively, yielding a cost saving of \u20ac51,738."
      },
      "Harms": {
        "score": 1,
        "evidence": "There was no statistically significant difference in the proportion of women who progressed to severe haemorrhage (\u2265\u20092000\u2009ml) between groups: 97/238 (40%) in the post\u2010ROTEM \u00ae group vs. 312/706 (44%) in the pre\u2010ROTEM group (p\u2009=\u20090.35)."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 9,
    "max_score": 25
  },
  "model": "gpt-4o"
}